Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure

The authors aimed to evaluate the effects of metoprolol succinate in combination with Entresto (Sacubitril Valsartan Sodium Tablets) on cardiac function and coagulation function in patients with congestive heart failure (CHF). A total of 120 patients were included in this study and patients were randomly assigned to control group and study group. In the control group, patients were prescribed with metoprolol succinate sustained-release tablets and the patients in the study group were prescribed with metoprolol succinate sustained-release tablets combined with Entresto. The following are key points to remember from this study on the management of patients with CHF treated with metoprolol succinate sustained-release tablets combined with Entresto: Take-Home Message No. 1 While comparing the clinical efficacy, the effective rates of study group and the control group were 98.33% and 90%, respectively. Take-Home Message No. 2 Before the treatment, no significant differences in cardiac function indexes and vascular endothelial function were observed. After the treatment in the study group, LVESD and LVEDD decreased and LVEF increased. Take-Home Message No. 3 In the study group, the levels of CGRP and ET increased but the levels of NO decreased after the treatment. Take-Home Message No. 4 No significant difference was observed in oxidative stress indexes before the treatment. After the treatment, levels of GSH-Px and SOD increased and the levels of MDA decreased in the study group. Take-Home Message No. 5 While comparing the indexes of blood coagulation function, no significant differences were observed before the treatment but after the treatment, levels of APTT, PT, and FIB in the study group decreased. Take-Home Message No. 6 Clinical studies showed that in CHF patients receiving Entresto and metoprolol together, LVESD and LVEDD reduced and LVEF increased, effectively promoting heart function and vascular endothelial function and lowering oxidative stress, blood coagulation indices, indicating that Entresto in combination with Metoprolol has good safety when improving ventricular remodelling. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.